DE102016115246C5 - Neue t-zellrezeptoren und deren verwendung in immuntherapie - Google Patents

Neue t-zellrezeptoren und deren verwendung in immuntherapie Download PDF

Info

Publication number
DE102016115246C5
DE102016115246C5 DE102016115246.3A DE102016115246A DE102016115246C5 DE 102016115246 C5 DE102016115246 C5 DE 102016115246C5 DE 102016115246 A DE102016115246 A DE 102016115246A DE 102016115246 C5 DE102016115246 C5 DE 102016115246C5
Authority
DE
Germany
Prior art keywords
tcr
antigen
seq
col6a3
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102016115246.3A
Other languages
German (de)
English (en)
Other versions
DE102016115246B3 (de
Inventor
Leonie ALTEN
Dominik Maurer
Steffen Walter
Sebastian Bunk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60419980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE102016115246(C5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to DE102016115246.3A priority Critical patent/DE102016115246C5/de
Priority to MDE20190706T priority patent/MD3500593T2/ro
Priority to SI201730961T priority patent/SI3500593T1/sl
Priority to SG11201900955VA priority patent/SG11201900955VA/en
Priority to DK17739220.6T priority patent/DK3500593T3/da
Priority to MX2019001769A priority patent/MX395287B/es
Priority to AU2017312361A priority patent/AU2017312361B2/en
Priority to MYPI2019000499A priority patent/MY195101A/en
Priority to BR112019001922A priority patent/BR112019001922A2/pt
Priority to IL264855A priority patent/IL264855B2/en
Priority to KR1020227010365A priority patent/KR20220044870A/ko
Priority to PCT/EP2017/066630 priority patent/WO2018033291A1/en
Priority to KR1020197006315A priority patent/KR102381854B1/ko
Priority to PE2019000285A priority patent/PE20190477A1/es
Priority to CN201780049787.2A priority patent/CN109563149A/zh
Priority to LTEPPCT/EP2017/066630T priority patent/LT3500593T/lt
Priority to HRP20211677TT priority patent/HRP20211677T1/hr
Priority to HUE17739220A priority patent/HUE057094T2/hu
Priority to PL17739220T priority patent/PL3500593T3/pl
Priority to CA3031995A priority patent/CA3031995A1/en
Priority to NZ750479A priority patent/NZ750479A/en
Priority to UAA201900959A priority patent/UA127162C2/uk
Priority to MA45976A priority patent/MA45976B1/fr
Priority to EP21192880.9A priority patent/EP3978520A1/en
Priority to EP17739220.6A priority patent/EP3500593B1/en
Priority to PT177392206T priority patent/PT3500593T/pt
Priority to CR20190095A priority patent/CR20190095A/es
Priority to JP2019508259A priority patent/JP6964351B2/ja
Priority to RS20211327A priority patent/RS62498B1/sr
Priority to ES17739220T priority patent/ES2897921T3/es
Priority to TW111115333A priority patent/TWI790162B/zh
Priority to TW106127257A priority patent/TWI775768B/zh
Priority to US15/677,651 priority patent/US10550182B2/en
Publication of DE102016115246B3 publication Critical patent/DE102016115246B3/de
Priority to US16/035,300 priority patent/US10526407B2/en
Application granted granted Critical
Publication of DE102016115246C5 publication Critical patent/DE102016115246C5/de
Priority to ZA2019/00664A priority patent/ZA201900664B/en
Priority to CL2019000366A priority patent/CL2019000366A1/es
Priority to PH12019500312A priority patent/PH12019500312A1/en
Priority to CONC2019/0002229A priority patent/CO2019002229A2/es
Priority to US16/402,829 priority patent/US10800845B2/en
Priority to US17/000,143 priority patent/US11939376B2/en
Priority to AU2021201518A priority patent/AU2021201518A1/en
Priority to JP2021128303A priority patent/JP2021184729A/ja
Priority to CY20211100944T priority patent/CY1124826T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE102016115246.3A 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie Expired - Fee Related DE102016115246C5 (de)

Priority Applications (43)

Application Number Priority Date Filing Date Title
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
MA45976A MA45976B1 (fr) 2016-08-17 2017-07-04 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
EP21192880.9A EP3978520A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
SG11201900955VA SG11201900955VA (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
DK17739220.6T DK3500593T3 (da) 2016-08-17 2017-07-04 Ukendte t-cellereceptorer og immunterapi under anvendelse deraf
MX2019001769A MX395287B (es) 2016-08-17 2017-07-04 Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
AU2017312361A AU2017312361B2 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
MYPI2019000499A MY195101A (en) 2016-08-17 2017-07-04 Novel T Cell Receptors and Immune Therapy Using the Same
BR112019001922A BR112019001922A2 (pt) 2016-08-17 2017-07-04 receptores de célula t e imunoterapia usando os mesmos
IL264855A IL264855B2 (en) 2016-08-17 2017-07-04 T-cell receptors and immunotherapy using them
KR1020227010365A KR20220044870A (ko) 2016-08-17 2017-07-04 T 세포 수용체 및 이를 사용하는 면역 요법
PCT/EP2017/066630 WO2018033291A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
KR1020197006315A KR102381854B1 (ko) 2016-08-17 2017-07-04 T 세포 수용체 및 이를 사용하는 면역 요법
SI201730961T SI3500593T1 (sl) 2016-08-17 2017-07-04 T-celični receptorji in imunska terapija z njihovo uporabo
CN201780049787.2A CN109563149A (zh) 2016-08-17 2017-07-04 T细胞受体及使用该t细胞受体的免疫治疗
LTEPPCT/EP2017/066630T LT3500593T (lt) 2016-08-17 2017-07-04 T ląstelių receptoriai ir imuninė terapija juos naudojant
HRP20211677TT HRP20211677T1 (hr) 2016-08-17 2017-07-04 T-stanični receptori i imunološka terapija koja koristi iste
HUE17739220A HUE057094T2 (hu) 2016-08-17 2017-07-04 T-sejt receptorok és a velük végzett immunterápia
PL17739220T PL3500593T3 (pl) 2016-08-17 2017-07-04 Receptory komórek t i immunoterapia z ich stosowaniem
CA3031995A CA3031995A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
NZ750479A NZ750479A (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
UAA201900959A UA127162C2 (uk) 2016-08-17 2017-07-04 Антигенрозпізнавальна структура, яка специфічно та/або селективно зв'язується з антигенним пептидом col6a3
MDE20190706T MD3500593T2 (ro) 2016-08-17 2017-07-04 Receptori de celule T și imunoterapie cu utilizarea acestora
EP17739220.6A EP3500593B1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same
PE2019000285A PE20190477A1 (es) 2016-08-17 2017-07-04 Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
PT177392206T PT3500593T (pt) 2016-08-17 2017-07-04 Recetores de células t e imunoterapia usando os mesmos
CR20190095A CR20190095A (es) 2016-08-17 2017-07-04 Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
JP2019508259A JP6964351B2 (ja) 2016-08-17 2017-07-04 新規ｔ細胞受容体およびそれを用いた免疫療法
RS20211327A RS62498B1 (sr) 2016-08-17 2017-07-04 T-ćelijski receptori i imunoterapija u kojoj se koriste
ES17739220T ES2897921T3 (es) 2016-08-17 2017-07-04 Receptores de linfocitos T e inmunoterapia basada en el uso de los mismos
TW106127257A TWI775768B (zh) 2016-08-17 2017-08-11 新穎t細胞受器及使用其之免疫治療
TW111115333A TWI790162B (zh) 2016-08-17 2017-08-11 新穎t細胞受器及使用其之免疫治療
US15/677,651 US10550182B2 (en) 2016-08-17 2017-08-15 T cell receptors and immune therapy using the same
US16/035,300 US10526407B2 (en) 2016-08-17 2018-07-13 T cell receptors and immune therapy using the same
ZA2019/00664A ZA201900664B (en) 2016-08-17 2019-01-31 T cell receptors and immune therapy using the same
CL2019000366A CL2019000366A1 (es) 2016-08-17 2019-02-12 Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
PH12019500312A PH12019500312A1 (en) 2016-08-17 2019-02-14 T cell receptors and immune therapy using the same
CONC2019/0002229A CO2019002229A2 (es) 2016-08-17 2019-03-11 Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
US16/402,829 US10800845B2 (en) 2016-08-17 2019-05-03 T cell receptors and immune therapy using the same
US17/000,143 US11939376B2 (en) 2016-08-17 2020-08-21 T cell receptors and immune therapy using the same
AU2021201518A AU2021201518A1 (en) 2016-08-17 2021-03-10 T cell receptors and immune therapy using the same
JP2021128303A JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法
CY20211100944T CY1124826T1 (el) 2016-08-17 2021-11-02 Υποδοχεις τ-κυτταρων και ανοσοθεραπεια με τη χρηση των ιδιων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie

Publications (2)

Publication Number Publication Date
DE102016115246B3 DE102016115246B3 (de) 2017-12-14
DE102016115246C5 true DE102016115246C5 (de) 2018-12-20

Family

ID=60419980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102016115246.3A Expired - Fee Related DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie

Country Status (18)

Country Link
US (2) US10550182B2 (enExample)
EP (1) EP3500593B1 (enExample)
JP (2) JP6964351B2 (enExample)
CN (1) CN109563149A (enExample)
AU (2) AU2017312361B2 (enExample)
BR (1) BR112019001922A2 (enExample)
CA (1) CA3031995A1 (enExample)
CR (1) CR20190095A (enExample)
DE (1) DE102016115246C5 (enExample)
DK (1) DK3500593T3 (enExample)
LT (1) LT3500593T (enExample)
MA (1) MA45976B1 (enExample)
MX (1) MX395287B (enExample)
PE (1) PE20190477A1 (enExample)
RS (1) RS62498B1 (enExample)
SG (1) SG11201900955VA (enExample)
TW (1) TWI775768B (enExample)
WO (1) WO2018033291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
CN111655280B (zh) 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
KR20250052472A (ko) 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법
JP7470640B2 (ja) 2018-02-09 2024-04-18 イマティクス ユーエス，アイエヌシー． Ｔ細胞を製造する方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US12195769B2 (en) 2018-06-19 2025-01-14 Dsm Ip Assets B.V. Lipolytic enzyme variants
AU2020211922B2 (en) * 2019-01-22 2025-05-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12R mutation
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3171370A1 (en) * 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
CN116096740A (zh) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
EP4408468A4 (en) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026046995A1 (en) * 2024-08-28 2026-03-05 Pairx Bio Pte. Ltd T cell receptors and uses thereof
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US8519100B2 (en) 2009-07-03 2013-08-27 Immunocore Ltd. Non-naturally occurring T cell receptors
WO2016011210A2 (en) * 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2006023382A2 (en) * 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
HRP20201351T1 (hr) * 2014-11-05 2020-11-27 Genentech, Inc. Postupci proizvodnje dvolančanih proteina u bakteriji

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US8519100B2 (en) 2009-07-03 2013-08-27 Immunocore Ltd. Non-naturally occurring T cell receptors
WO2016011210A2 (en) * 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Bertini et al., 2002 Eur. J. Paediatr. Neurol 6:193-8
C.A. Janeway et al. (eds.), Immunobiology, 8 Ed., Garland Publishing, New York, NY (201 1)
DATABASE EMBL [online] "Homo sapiens (human) partial T cell receptor alpha chain V-J-region", XP002774329, retrieved from EBI *
Datenbank EMBL, "Homo sapiens (human) partial T cell receptor alpha chain V-J-region", XP002774329, EBI Eintragungsnummer BAS03375 vom 30.07.2015
Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press (1988)
Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984)
Hirano N. et al; Blood. 2006 Feb 15;107(4):1528-36
Huse et al., Science, 246, 1275-81 (1989)
Qiao J et al. „Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics" Oncotarget. 2015 Oct 6; 6(30): 29929-29946
QIAO, J. [u.a.]: Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics. Oncotarget (2015) 6 (30) 29929-46 *
Roder et al, Methods Enzymol, 121, 140-67 (1986)
Smith MJ, et al. „Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification" British journal of cancer. 2009;100:1452-1464
Tilman G et al „Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells" Mol Cancer. 2007;6:80
Willcox BE et al., 1999 Protein Sci., Nov;8(11):2418-23
z.B. Kohler and Milstein, Eur. J. Immunol, 5, 51 1-519 (1976)

Also Published As

Publication number Publication date
RS62498B1 (sr) 2021-11-30
TW201806973A (zh) 2018-03-01
SG11201900955VA (en) 2019-03-28
MA45976A (fr) 2021-05-19
TWI775768B (zh) 2022-09-01
BR112019001922A2 (pt) 2019-07-09
US10550182B2 (en) 2020-02-04
US20180319884A1 (en) 2018-11-08
EP3500593A1 (en) 2019-06-26
LT3500593T (lt) 2021-11-25
AU2017312361B2 (en) 2020-12-10
US20180051080A1 (en) 2018-02-22
AU2017312361A1 (en) 2019-02-28
AU2021201518A1 (en) 2021-04-01
CN109563149A (zh) 2019-04-02
DE102016115246B3 (de) 2017-12-14
CA3031995A1 (en) 2018-02-22
EP3500593B1 (en) 2021-08-25
DK3500593T3 (da) 2021-11-01
CR20190095A (es) 2019-06-13
MX2019001769A (es) 2019-07-08
MX395287B (es) 2025-03-25
JP2021184729A (ja) 2021-12-09
PE20190477A1 (es) 2019-04-04
WO2018033291A1 (en) 2018-02-22
JP2019528061A (ja) 2019-10-10
JP6964351B2 (ja) 2021-11-10
MA45976B1 (fr) 2021-09-30
US10526407B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
DE102016115246B3 (de) Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123859B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123847B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
US11111286B2 (en) T cell receptors and immune therapy using the same against PRAME positive cancers
EP3600409B1 (en) T cell receptors and immune therapy using the same against prame positive cancers
EP3645573B1 (en) Novel t cell receptors and immune therapy using the same
US11939376B2 (en) T cell receptors and immune therapy using the same
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
DE102017125888A1 (de) Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
HK40071461A (en) T cell receptors and immune therapy using the same
HK40117524A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40010473B (en) T cell receptors and immune therapy using the same
HK40020731B (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40014640B (en) Novel t cell receptors and immune therapy using the same
HK40014640A (en) Novel t cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R016 Response to examination communication
R018 Grant decision by examination section/examining division
R046 Limitation request validly filed
R026 Opposition filed against patent
R050 Examing division/federal patent court decision limiting patent now final
R206 Amended patent specification
R082 Change of representative

Representative=s name: ZSP PATENTANWAELTE PARTG MBB, DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R082 Change of representative

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R031 Decision of examining division/federal patent court maintaining patent unamended now final
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee